Review



sdma  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc sdma
    Sdma, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 210 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sdma/product/Cell Signaling Technology Inc
    Average 96 stars, based on 210 article reviews
    sdma - by Bioz Stars, 2026-06
    96/100 stars

    Images



    Similar Products

    sdma  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc sdma
    Sdma, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sdma/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    sdma - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    anti sdma  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc anti sdma
    Anti Sdma, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti sdma/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    anti sdma - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    antibodies sdma  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc antibodies sdma
    In vivo PRMT5i treatment induces a rapid shift towards progressed disease. a. Scheme of the in vivo treatment experiment. b. Relative luminescence of each of the treatment arms. Data are mean ± SEM. p=n.s. for each timepoint, Student’s t-test. n=6-7 recipients/condition. c. Representative lung histology sections from recipients given the indicated treatments, including <t>H&E,</t> <t>luciferase</t> IHC, and <t>SDMA</t> IHC. d. Lung tumor burden analysis of each treatment arm. Data are mean ± SEM. p=0.8162 for 3mg/kg and p=0.1401 for 10mg/kg, as compared to Vehicle, Students’ t-test. n=6-7 recipients/condition. e. Lung tumor grade analysis of each treatment arm. Data are mean ± SEM. For Grade 4 tumor percentage, p=0.0002 for 3mg/kg and p=0.0007 for 10mg/kg, as compared to Vehicle, Students’ t-test. n=6-7 recipients/condition.
    Antibodies Sdma, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies sdma/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    antibodies sdma - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    In vivo PRMT5i treatment induces a rapid shift towards progressed disease. a. Scheme of the in vivo treatment experiment. b. Relative luminescence of each of the treatment arms. Data are mean ± SEM. p=n.s. for each timepoint, Student’s t-test. n=6-7 recipients/condition. c. Representative lung histology sections from recipients given the indicated treatments, including H&E, luciferase IHC, and SDMA IHC. d. Lung tumor burden analysis of each treatment arm. Data are mean ± SEM. p=0.8162 for 3mg/kg and p=0.1401 for 10mg/kg, as compared to Vehicle, Students’ t-test. n=6-7 recipients/condition. e. Lung tumor grade analysis of each treatment arm. Data are mean ± SEM. For Grade 4 tumor percentage, p=0.0002 for 3mg/kg and p=0.0007 for 10mg/kg, as compared to Vehicle, Students’ t-test. n=6-7 recipients/condition.

    Journal: bioRxiv

    Article Title: PRMT5 inhibitors actively promote metastatic progression of lung adenocarcinoma

    doi: 10.64898/2026.01.30.702866

    Figure Lengend Snippet: In vivo PRMT5i treatment induces a rapid shift towards progressed disease. a. Scheme of the in vivo treatment experiment. b. Relative luminescence of each of the treatment arms. Data are mean ± SEM. p=n.s. for each timepoint, Student’s t-test. n=6-7 recipients/condition. c. Representative lung histology sections from recipients given the indicated treatments, including H&E, luciferase IHC, and SDMA IHC. d. Lung tumor burden analysis of each treatment arm. Data are mean ± SEM. p=0.8162 for 3mg/kg and p=0.1401 for 10mg/kg, as compared to Vehicle, Students’ t-test. n=6-7 recipients/condition. e. Lung tumor grade analysis of each treatment arm. Data are mean ± SEM. For Grade 4 tumor percentage, p=0.0002 for 3mg/kg and p=0.0007 for 10mg/kg, as compared to Vehicle, Students’ t-test. n=6-7 recipients/condition.

    Article Snippet: Sections were stained for 1 hour with the following antibodies SDMA (Cell Signaling Technology, 13222S, 1:2500), Luciferase (Sigma, L2164, 1:500, TE Buffer, pH 9).

    Techniques: In Vivo, Luciferase